SCM Lifescience Co. Ltd
SCM Lifescience Co., Ltd. operates as a stem cell therapy company in South Korea. It develops SCM-AGH, a treatment for moderate to severe acute pancreatitis and moderate to severe atopic dermatitis, as well as chronic graft versus host disease; and Iroro Deerscalp, a toothbrush cosmetic for hair loss relief. The company was founded in 2014 and is headquartered in Incheon, South Korea.
SCM Lifescience Co. Ltd - Asset Resilience Ratio
SCM Lifescience Co. Ltd (298060) has an Asset Resilience Ratio of 4.67% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how SCM Lifescience Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down SCM Lifescience Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩2.06 Billion | 4.67% |
| Total Liquid Assets | ₩2.06 Billion | 4.67% |
Asset Resilience Insights
- Limited Liquidity: SCM Lifescience Co. Ltd maintains only 4.67% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SCM Lifescience Co. Ltd Industry Peers by Asset Resilience Ratio
Compare SCM Lifescience Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for SCM Lifescience Co. Ltd (2017–2024)
The table below shows the annual Asset Resilience Ratio data for SCM Lifescience Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.97% | ₩919.76 Million | ₩23.17 Billion | -44.59pp |
| 2023-12-31 | 48.56% | ₩12.34 Billion | ₩25.40 Billion | +21.39pp |
| 2022-12-31 | 27.16% | ₩8.97 Billion | ₩33.02 Billion | -7.79pp |
| 2021-12-31 | 34.95% | ₩18.89 Billion | ₩54.04 Billion | -9.84pp |
| 2020-12-31 | 44.79% | ₩34.17 Billion | ₩76.29 Billion | -10.06pp |
| 2019-12-31 | 54.84% | ₩22.51 Billion | ₩41.04 Billion | -32.94pp |
| 2018-12-31 | 87.78% | ₩38.50 Billion | ₩43.86 Billion | +9.21pp |
| 2017-12-31 | 78.57% | ₩5.06 Billion | ₩6.44 Billion | -- |